🟢 Moderna is trading 5% up; no clear catalyst identified

Moderna is trading 5.35% higher at $207.84 on September 29, 2026, with no reliable report identifying a specific catalyst.

• Major indices are nearly flat, and the provided context does not point to a broad-market move.
• A Delaware judge’s September 28 decision allowed Bayer’s mRNA patent lawsuits to proceed. Reuters reports the suits concern alleged use of Monsanto mRNA technology in COVID-19 vaccines; the decision is a potential legal overhang, not an evident explanation for the gain.